Helix Scout is an AI agent that continuously monitors scientific papers, patent filings, clinical trials, and funding rounds to surface the biotech startups that matter, before anyone else sees them.
Over 2 million biomedical papers are published every year. No analyst team can read them all. Breakthroughs get buried in the volume.
By the time a startup shows up on PitchBook, the seed round is closed. The signal was in the science months before the press release.
Existing deal intelligence platforms track millions of companies across all sectors. None deeply understand biotech science or evaluate therapeutic potential.
Even the best biotech VCs depend on small analyst teams doing manual screening. The fund that sees more, evaluated faster, wins more deals.
Helix Scout ingests papers from PubMed, bioRxiv, and medRxiv. Tracks patent filings across USPTO and EPO. Monitors clinical trial registrations and funding announcements in real-time.
Goes beyond keyword matching. Evaluates therapeutic mechanism novelty, assesses clinical trial design quality, and identifies papers that represent genuine scientific advances versus incremental work.
Links scientific breakthroughs to the startups commercializing them. Identifies founding teams with relevant domain expertise. Maps IP portfolios to business potential.
Every morning, a curated brief of emerging biotech opportunities. Ranked by scientific merit, team strength, and market timing. Ready for your investment committee.
The fund that reads every paper, tracks every patent, and evaluates every startup, wins. Helix Scout makes that fund yours.